Similarly, DFS of radiotherapied patients with overexpression of two-protein combined panel was significantly worse than that of patients with lower expression (Fig 2D, P = 0.028), implicating that the MRE11/ATM two-protein panel has specific potential as a predictive marker of tumour response to radiotherapy. The gene discussed is MRE11; the disease is neoplasm.